We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Marina Biotech Announces First Human Use of its Proprietary Delivery Technology

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Marina Biotech Announces First Human Use of its Proprietary Delivery Technology"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
Marina Biotech, Inc. has announced that the first patient has received a novel cancer therapeutic candidate formulated in the Company's proprietary SMARTICLES® delivery technology.

ProNAi Therapeutics Inc., a privately held biopharmaceutical company and licensee of the SMARTICLES technology, dosed their first patient in a Phase I clinical study of PNT2258 in patients with advanced solid tumors. PNT2258 is an oligonucleotide therapeutic encapsulated within a SMARTICLES formulation.

The SMARTICLES delivery technology was developed by Novosom AG and acquired by Marina Biotech in July 2010. The SMARTICLES delivery technology is part of a broad and comprehensive patent estate surrounding amphoteric liposomal delivery now owned by Marina Biotech.

"The first dosing of this novel nucleic acid-based therapeutic is the culmination of tremendous effort on the part of both ProNAi and Novosom over the last several years," stated J. Michael French, President and Chief Executive Officer of Marina Biotech. "We are pleased to see a SMARTICLES formulation advance into human clinical testing. We hope to see significant advancement of our amphoteric liposomal delivery technology over the coming months with this first-in-human experience with ProNAi coupled with the further development of this technology in our RNAi-based drug discovery platforms."

The Phase 1 clinical trial is a single-center, open labeled dose escalation study of PNT2258 administered intravenously in cancer patient volunteers. The primary objective is to assess the safety and tolerability of PNT2258. The study will also examine the pharmacokinetics of PNT2258 and explore biomarkers with the goal of identifying doses for subsequent efficacy studies in cancer patients.